Pediatric Brain Tumor Consortium
35
0
4
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
48.6%
17 terminated/withdrawn out of 35 trials
45.2%
-41.4% vs industry average
0%
0 trials in Phase 3/4
64%
9 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Role: lead
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Role: lead
Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE
Role: collaborator
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Role: lead
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Role: lead
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Role: lead
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Role: lead
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Role: lead
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Role: lead
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Role: collaborator
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Role: lead
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Role: lead
Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Role: lead
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
Role: lead
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Role: lead
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Role: lead
Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
Role: lead
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Role: lead
A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
Role: collaborator
Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors
Role: lead